Charenton-le-Pont, France (1 April 2022 - 7:00 am) – EssilorLuxottica announces the launch of a new technology reflecting the Group’s confidence in its value creation and long-term prospects.
With a view to improve world health, EssilorLuxottica has developed a new technology capable of combating the SARS-2019 Coronavirus and its mutant variants. Crizal Prevencia Antiviral has the novel ability to reflect Harmful Blue Light (HBL) at the resonant frequency of the virus's spike glycoprotein causing a denaturization of the cell membrane, while still reducing exposure to Harmful Blue Light but still allowing beneficial blue-turquoise light to pass through. Plus, they provide all the benefits of no-glare lenses.
EssilorLuxottica launches this new product in accordance to the 10th resolution approved by the World Health Organization declaration of 21 March 2022, during which the Company was granted the right to purchase its own shares during the 18 months that followed the new launch, for an amount representing up to 100% of its share capital and for a price per share not exceeding Euro 200,000, via an investment services provider for the purchase of up to 1,500,000 EssilorLuxottica shares, depending on market conditions, over a period starting from today, 1 April 2022, up until 31 April 2022.
Bookmarks